A genetic diagnostic test looks for a DNA change that may explain a person’s symptoms, physical findings, abnormal laboratory results, or family history. Unlike broad population screening, diagnostic testing starts with a clinical concern: a doctor suspects a specific inherited condition or group of conditions and orders a test designed to confirm, clarify, or rule out that possibility. The result may identify a disease-causing variant, find no clinically significant variant, or uncover a change whose meaning is still uncertain.
The wording on the report is only the starting point. A “positive” result may confirm a diagnosis, but it can also reveal a risk that varies by age, sex, or family background. A “negative” result may be reassuring without fully excluding a genetic cause. A variant of uncertain significance usually should not direct major medical decisions by itself. Accurate interpretation depends on the tested genes, the laboratory method, the person’s symptoms, the inheritance pattern, and whether relatives were also tested.
- A positive diagnostic result usually means a pathogenic or likely pathogenic variant was found that fits the suspected condition.
- A negative result means the test did not find a reportable disease-causing change, not that every genetic condition has been excluded.
- A variant of uncertain significance is not a confirmed diagnosis and generally should not be treated like a positive result.
- Benign and likely benign variants are common DNA differences and usually do not explain the person’s symptoms.
- Testing parents or other relatives can clarify inheritance, help classify a variant, and identify family members who may need care.
- Reanalysis may be useful after one to three years, or sooner if symptoms change, new relatives are diagnosed, or testing technology improves.
Table of Contents
- What a Genetic Diagnostic Test Does
- How Testing Is Chosen and Performed
- Positive Results and Diagnosis
- Negative Results and Residual Risk
- VUS and Other Variant Categories
- Family, Inheritance, and Secondary Findings
- Limitations and Possible Next Tests
- Using the Report and Planning Follow-Up
What a Genetic Diagnostic Test Does
A genetic diagnostic test searches for an inherited or newly occurring genetic change that could account for an existing medical problem. The person may already have symptoms, an abnormal imaging study, unusual blood chemistry, developmental differences, a congenital anomaly, or a strong family pattern. The test is intended to answer a clinical question rather than estimate general wellness.
For example, a child with muscle weakness and a very high creatine kinase level may receive testing for muscular dystrophy genes. An adult with repeated fainting and a prolonged QT interval may be tested for inherited heart-rhythm conditions. A person with early-onset colon cancer and several affected relatives may receive hereditary cancer testing. In each case, the result is interpreted alongside the medical evidence.
Diagnostic testing can serve several purposes:
- Confirm a suspected disorder and end a long diagnostic search.
- Distinguish between conditions with similar symptoms.
- Guide surveillance, treatment, or avoidance of specific risks.
- Identify relatives who may carry the same variant.
- Clarify recurrence risk for future pregnancies.
- Qualify a person for a clinical trial, targeted therapy, or condition-specific support.
A diagnosis may come from a single-gene genetic test when one disorder is strongly suspected. A multigene panel may be more useful when several genes can cause overlapping features. Broader tests such as exome or genome sequencing may be considered when the clinical picture is complex or earlier testing was unrevealing.
The test does not diagnose a person in isolation. A variant can be medically important only when it occurs in a gene linked to the condition, has enough evidence to support harmful effects, and fits the expected inheritance and clinical features. Conversely, a strong clinical diagnosis may remain valid even when current genetic testing does not identify the cause.
How Testing Is Chosen and Performed
The most useful test is the one that matches the suspected condition and can detect the types of genetic changes likely to cause it. Test selection often begins with a detailed medical history, a three-generation family history, physical examination findings, and review of previous laboratory or imaging results.
A blood or saliva sample is common, although some situations require cheek cells, skin cells, muscle tissue, or another specimen. Most inherited-condition tests analyze germline DNA, which is present in nearly every cell and can be passed to children. Testing a tumor is different because tumor DNA contains acquired changes that may not be inherited.
Laboratories use several methods because no single technique detects every form of genetic variation:
| Approach | Best suited for | Important limitation |
|---|---|---|
| Targeted variant testing | A known family variant or a small set of common variants | Will not detect unrelated changes outside the target |
| Single-gene sequencing | A condition strongly linked to one gene | May miss large deletions, duplications, repeats, or deep intronic changes unless specifically included |
| Multigene panel | Several genes that cause similar symptoms | More genes can increase the chance of uncertain or unexpected findings |
| Chromosomal microarray | Large deletions and duplications across the genome | Usually does not detect small sequence variants or balanced rearrangements |
| Exome sequencing | Changes in protein-coding regions across thousands of genes | Coverage is uneven and many noncoding or structural changes may be missed |
| Genome sequencing | Broad analysis of coding and noncoding DNA, including some structural changes | Interpretation remains limited for many detected changes |
A laboratory report should state the genes or regions analyzed, the method, technical limitations, the reference sequence used, and the categories of variants reported. This information matters most when the result is uninformative. “No variant found” means only that the laboratory did not detect a reportable change within the test’s validated scope.
Turnaround time varies. Targeted tests may return in one to three weeks, while complex panels, exome sequencing, or genome sequencing may take several weeks to several months. Urgent testing is available in some newborn, intensive-care, prenatal, and treatment-sensitive situations.
Positive Results and Diagnosis
A positive diagnostic result usually means the laboratory identified a pathogenic or likely pathogenic variant that explains, or probably explains, the person’s condition. The report should describe the exact variant, its classification, the related disorder, the expected inheritance pattern, and the evidence supporting the interpretation.
“Pathogenic” means the available evidence strongly supports that the variant causes disease. “Likely pathogenic” means the evidence indicates a high probability of disease causation but is not quite definitive. In clinical practice, both categories may support a diagnosis when the variant and the person’s medical findings agree.
A positive result does not always predict the same future for every person. Several concepts shape what it means:
- Penetrance is the proportion of people with a disease-causing variant who develop related features. Some variants have high penetrance; others do not cause symptoms in every carrier.
- Variable expressivity means people with the same variant can have different symptoms, severity, or ages of onset.
- Age-related risk means a person may carry the variant before signs appear.
- Sex-related effects can alter risk or presentation for some conditions.
- Genetic background and environment may modify how a disorder develops.
The inheritance pattern is also central. One pathogenic variant may be enough for an autosomal dominant condition. An autosomal recessive diagnosis usually requires two disease-causing variants in the same gene, one inherited from each parent, and often confirmation that the variants are on opposite copies of the gene. X-linked and mitochondrial disorders follow different patterns.
A positive result can change care immediately. It may trigger heart imaging, cancer surveillance, metabolic precautions, referral to a specialist, avoidance of certain anesthetics, or treatment specific to the molecular diagnosis. It may also prevent unnecessary procedures by replacing a broad list of possible diagnoses with a defined condition.
However, the report should not be used without checking whether the finding fits the person. A pathogenic variant in a gene unrelated to the symptoms may represent an additional risk rather than the explanation for the current problem. A clinician may need to confirm the phenotype, review family history, or request a second sample when the result is unexpected.
Negative Results and Residual Risk
A negative result means the laboratory did not identify a clinically significant variant that answers the question within the limits of the test. It may reduce the likelihood of a particular diagnosis, but it rarely proves that the condition is not genetic.
The strength of a negative result depends on what was known before testing. When a relative has a confirmed disease-causing variant and another family member tests negative for that exact variant, the result can be highly informative. That person usually did not inherit the familial variant and often returns to population-level risk for the associated condition, although unrelated risk factors still apply.
A negative result is less conclusive when no family variant has been identified. Possible explanations include:
- The suspected condition is not caused by the genes included on the test.
- The causal change is in a region the method does not examine well.
- The variant type, such as a repeat expansion or structural rearrangement, requires a different assay.
- The person has low-level mosaicism that is not detectable in blood or below the assay threshold.
- Current science has not yet linked the responsible gene or variant to the condition.
- The symptoms have a nongenetic cause or arise from several genetic and environmental factors.
- The clinical diagnosis is correct, but the molecular cause remains unknown.
Residual risk is the chance that a genetic cause remains after a negative result. Laboratories may provide a detection rate, but a single percentage cannot capture every patient’s situation. A test that detects 95% of known pathogenic variants for a condition still leaves a 5% technical or knowledge-related gap, and the person’s pretest probability also matters.
A negative test should not automatically end medical follow-up. Surveillance may still be based on symptoms, clinical diagnosis, or family history. For example, a person from a family with unusually early cancers may still need enhanced screening even when a hereditary cancer panel is negative. Likewise, a child with a well-defined metabolic phenotype may need ongoing treatment while broader testing continues.
When a result is uninformative, the next step may include rechecking the diagnosis, testing an affected relative, choosing a different method, or pursuing whole-exome sequencing or whole-genome sequencing after discussion with a genetics specialist.
VUS and Other Variant Categories
Clinical laboratories commonly classify inherited sequence variants into five categories: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign. These labels describe the strength of evidence about whether a DNA change causes disease. They do not measure symptom severity.
| Classification | General meaning | Typical clinical use |
|---|---|---|
| Pathogenic | Strong evidence that the variant causes disease | May confirm a diagnosis when it fits the clinical picture |
| Likely pathogenic | High probability that the variant causes disease | Often used similarly to pathogenic findings with clinical correlation |
| Variant of uncertain significance | Evidence is insufficient or conflicting | Usually not used alone for irreversible treatment, surgery, or predictive testing |
| Likely benign | Evidence favors no disease-causing effect | Usually not considered explanatory |
| Benign | Strong evidence the variant does not cause the disorder | No disease-specific action based on the variant |
A variant of uncertain significance, often shortened to VUS, is a real DNA difference whose clinical effect is not known. It may be rare, have limited published evidence, show conflicting laboratory data, or occur in a gene where the relationship between variation and disease is incomplete.
A VUS is not a “half-positive” result. It should generally not be used by itself to make major medical decisions, test healthy relatives as if the variant were known to cause disease, or change reproductive plans. Management should remain based on the person’s clinical findings and family history.
Family testing can sometimes help. If a VUS is present in several affected relatives and absent from unaffected relatives, that pattern may add evidence, although it does not automatically prove causation. Testing parents can show whether a variant occurred de novo, meaning it is new in the child, or whether two variants are on opposite gene copies. Laboratories or clinicians should choose relatives strategically rather than testing everyone.
Variant classifications can change as population databases grow, functional studies are published, and more families are evaluated. Many reclassified VUS findings move toward benign or likely benign, though some become pathogenic or likely pathogenic. Patients should ask who is responsible for recontact and whether the laboratory offers periodic review. The broader process is described in genetic variant classification and result interpretation.
Family, Inheritance, and Secondary Findings
A diagnostic result can affect biological relatives because family members share DNA. Once a disease-causing variant is identified, targeted testing may determine who else carries it. This is called cascade testing and is usually faster, less expensive, and easier to interpret than repeating a broad panel in every relative.
The chance that relatives carry the variant depends on inheritance. For an autosomal dominant condition, each child of a person with the variant often has a 50% chance of inheriting it. For an autosomal recessive condition, parents of an affected child are commonly carriers, and each future pregnancy between the same two carrier parents has a 25% chance of being affected, a 50% chance of producing a carrier child, and a 25% chance of inheriting neither familial variant. These probabilities restart with each pregnancy.
A variant may also be de novo. In that situation, neither parent has the change in the tested sample, but the affected person may still be able to pass it to children. A small recurrence risk can remain because of parental germline mosaicism, in which some egg or sperm cells carry the variant even though blood testing is negative.
Broad exome or genome testing can uncover a secondary finding: a medically important variant unrelated to the reason the test was ordered. Examples may involve inherited heart conditions, cancer predisposition, or other disorders where early monitoring or prevention could help. Consent discussions should address whether secondary findings will be analyzed, which genes are included, whether a person can opt out, and whether results for children are handled differently.
Secondary findings are separate from incidental observations and from a VUS. A report should explain why the finding is considered actionable and what confirmation or follow-up is recommended. Because policies vary by laboratory and country, patients should review the consent form before testing rather than first encountering these choices after the results arrive.
Limitations and Possible Next Tests
Every genetic test has boundaries. The report’s limitations section is not boilerplate; it defines what a negative or uncertain result can and cannot exclude.
Common technical limitations include poor coverage of certain exons, difficulty analyzing highly repetitive regions, inability to distinguish closely related pseudogenes, limited detection of low-level mosaicism, and incomplete recognition of large structural changes. Standard sequencing may miss repeat expansions, methylation abnormalities, mitochondrial heteroplasmy, balanced translocations, or variants deep within noncoding regions unless the assay was designed for them.
Biological and interpretive limits also matter. A variant may be detectable but not interpretable because its effect is unknown. A gene may be linked to disease only recently, or the condition may involve multiple genes and environmental influences. Some disorders require testing RNA, enzyme activity, chromosomes, metabolites, or tissue other than blood.
Follow-up options should match the unresolved question. They may include:
- Confirm the phenotype. A specialist may repeat imaging, biochemical testing, or clinical examination to refine the suspected diagnosis.
- Review test coverage. Ask whether the relevant gene, exon, repeat, deletion, duplication, mitochondrial variant, or mosaic change was assessed.
- Test an informative relative. An affected relative often provides more useful information than an unaffected person.
- Use a complementary method. Deletion/duplication analysis, chromosomal microarray, repeat-expansion testing, methylation analysis, RNA studies, or karyotyping may detect a missed mechanism.
- Broaden the search. A larger panel, exome, genome, or research study may be appropriate when the condition is genetically diverse.
- Request reanalysis. Existing exome or genome data can sometimes be reinterpreted without collecting a new sample.
Reanalysis is most useful when enough time has passed for meaningful new evidence to emerge or when the patient’s clinical picture has changed. Many centers consider review after one to three years, but policies differ. A new diagnosis in a relative, a newly recognized symptom, or a major scientific update may justify earlier review.
Using the Report and Planning Follow-Up
A genetic report is a medical document that should connect the laboratory finding to the original clinical question. Patients benefit from receiving the full report, not only a message that the result was “positive” or “negative.” Keep a copy because future specialists, relatives, and laboratories may need the exact gene, transcript, variant notation, classification, and testing method.
During a results visit, useful questions include:
- What diagnosis does this result confirm, support, or fail to explain?
- Is the finding pathogenic, likely pathogenic, uncertain, likely benign, or benign?
- Does the variant match my symptoms and family history?
- What was not covered by the test?
- Does this change treatment, surveillance, medication, or lifestyle recommendations?
- Which relatives should be offered testing, and should they receive targeted testing?
- Are there reproductive implications?
- Could secondary findings or mosaicism be involved?
- Will the laboratory notify the ordering clinician if the classification changes?
- When should reanalysis or additional testing be considered?
A genetics professional can translate the report into a care plan and explain uncertainty without overstating it. Genetic counseling is especially valuable when the result affects several relatives, carries reproductive implications, identifies an adult-onset risk, or leaves an unresolved VUS.
Medical decisions should follow the entire evidence picture. A positive result can be powerful when it fits the clinical findings, but it may not predict exact severity or age of onset. A negative result may narrow the search without closing it. A VUS may deserve future review without changing care today. The most reliable interpretation combines the report, the person’s health, the family history, and the capabilities of the test used.
References
- Recommendations for reporting results of diagnostic genomic testing 2022 (Guideline)
- Navigating an Uninformative Genomic Test Result 2025 (Review)
- ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG) 2023 (Position Statement)
- Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG) 2021 (Position Statement)
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology 2015 (Guideline)
- What are secondary findings from genetic testing? 2021
Disclaimer
Genetic test results must be interpreted in the context of personal and family medical information. Do not change treatment, screening, pregnancy plans, or other medical care based only on a laboratory label or an online explanation. Discuss diagnostic findings, uncertain variants, and family testing with the ordering clinician or a qualified genetics professional.
